OPTHEA LTD Total Liabilities
OPTHEA LTD total liabilities. Based on the latest financial reports, OPTHEA LTD (UKJ) has total liabilities worth €314.48 Million EUR (≈ $367.65 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of OPTHEA LTD to measure how many days the company can operate on defensive assets alone.
Total Liabilities of OPTHEA LTD (2022–2025)
Total liabilities of OPTHEA LTD from 2022 to 2025. This chart illustrates how OPTHEA LTD's total liabilities have evolved over time, based on quarterly financial data.
OPTHEA LTD Competitors by Total Liabilities
The table below lists competitors of OPTHEA LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
USA | $7.32 Million |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
USA | $0.00 |
|
Kolon Corp
KO:002025
|
Korea | ₩5.21 Trillion |
|
Palatin Technologies, Inc. Common Stock
NASDAQ:PTN
|
USA | $2.63 Million |
|
In8bio Inc
NASDAQ:INAB
|
USA | $3.38 Million |
|
CWG Holdings Bhd
KLSE:9423
|
Malaysia | RM39.59 Million |
|
Nuchev Ltd
AU:NUC
|
Australia | AU$6.16 Million |
|
Spring Art Holdings Bhd
KLSE:0216
|
Malaysia | RM17.85 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down OPTHEA LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OPTHEA LTD balance sheet assets.
Liquidity & Leverage Metrics
OPTHEA LTD Total Liabilities Ratios Explained
OPTHEA LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OPTHEA LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OPTHEA LTD (2022–2025)
The table below shows the annual total liabilities of OPTHEA LTD from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €257.87 Million ≈ $301.47 Million |
-2.54% |
| 2024-06-30 | €264.60 Million ≈ $309.35 Million |
+153.22% |
| 2023-06-30 | €104.49 Million ≈ $122.17 Million |
+765.76% |
| 2022-06-30 | €12.07 Million ≈ $14.11 Million |
-- |
About OPTHEA LTD
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macula… Read more